Mergers & Acquisitions
By The Online Investor Staff, updated Wed., Dec. 11, 4:09 PM
Slide #77. Roche — Poseida Therapeutics, Inc.
Acquirer: |
Roche |
Acquiree: |
Poseida Therapeutics, Inc. (NASDAQ:PSTX) |
Details: |
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. ("Poseida", NASDAQ:PSTX), a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida's R&D portfolio includes pre-clinical and clinical-stage off-the-shelf (also referred to as allogeneic) CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms. |
Open the PSTX Page at The Online Investor »
Company Name: |
Poseida Therapeutics Inc |
Website: |
www.poseida.com |
Sector: |
Biotechnology |
Number of ETFs Holding PSTX: |
35 |
Total Market Value Held by ETFs: |
$80.09M |
Total Market Capitalization: |
$920.00M |
% of Market Cap. Held by ETFs: |
8.71% |
|
Open the PSTX Page at The Online Investor (in a new window) »
|
December 11, 2024 4:09 PM Eastern
Hold (2.00 out of 4)
0th percentile
|
|